Canaccord Genuity Initiates Coverage On Tonix Pharmaceuticals with Buy Rating, Announces Price Target of $18

Benzinga · 3d ago
Canaccord Genuity analyst Gary Nachman initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Buy rating and announces Price Target of $18.